We are live on ! Find out more
AG

Artal Group Portfolio holdings

AUM $1.01B
1-Year Est. Return 29.84%
This Fund
S&P 500
This Quarter Est. Return
+8.65%
1 Year Est. Return
+29.84%
3 Year Est. Return
+144%
5 Year Est. Return
+76.57%
10 Year Est. Return
+1,417.6%
AUM
$6.63B
AUM Growth
+$825M
Cap. Flow
+$471M
Cap. Flow %
7.11%
Top 10 Hldgs %
82.61%
Holding
140
New
29
Increased
38
Reduced
20
Closed
21

Top Buys

Rank Stock Value
1
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$25.1M
2
INCY icon
Incyte
INCY
+$10.5M
3
DNLI icon
Denali Therapeutics
DNLI
+$8.99M
4
LXRX icon
Lexicon Pharmaceuticals
LXRX
+$7.86M
5
ALBO
Albireo Pharma Inc
ALBO
+$7.61M

Top Sells

Rank Stock Value
1
NKTR icon
Nektar Therapeutics
NKTR
+$33.5M
2
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$17.4M
3
RXDX
Ignyta, Inc.
RXDX
+$11.1M
4
NBIX icon
Neurocrine Biosciences
NBIX
+$10.2M
5
SRPT icon
Sarepta Therapeutics
SRPT
+$9.07M

Sector Composition

Rank Sector Weight
1 Consumer Staples 43.26%
2 Consumer Discretionary 19.67%
3 Healthcare 17.59%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AGEN
51
Agenus
AGEN
$276M
$8.15M 0.12%
127,388
+13
+0% +$992
ZTO icon
52
CALL
ZTO Express
ZTO
$18.2B
$7.92M 0.12%
+500,000
New +$7.88M
DNLI icon
53
Denali Therapeutics
DNLI
$3.79B
$7.82M 0.12%
+500,000
New +$8.99M
IRWD icon
54
Ironwood Pharmaceuticals
IRWD
$586M
$7.75M 0.12%
617,154
-358,200
-37% -$4.68M
ALBO
55
DELISTED
Albireo Pharma Inc
ALBO
$7.68M 0.12%
+300,000
New +$7.61M
BPMC
56
DELISTED
Blueprint Medicines
BPMC
$7.54M 0.11%
+100,000
New +$7.04M
PTLA
57
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
$7.3M 0.11%
+150,000
New +$7.59M
HZNP
58
CALL
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$7.3M 0.11%
500,000
– –
CLVS
59
DELISTED
Clovis Oncology, Inc.
CLVS
$6.8M 0.1%
100,000
-15,000
-13% -$1.05M
ACIU icon
60
AC Immune
ACIU
$231M
$6.4M 0.1%
500,000
– –
ARRY
61
CALL
DELISTED
Array Biopharma Inc
ARRY
$6.4M 0.1%
500,000
-500,000
-50% -$5.69M
BOLD
62
DELISTED
Audentes Therapeutics, Inc
BOLD
$6.25M 0.09%
200,000
– –
PRQR icon
63
ProQR Therapeutics
PRQR
$244M
$6.13M 0.09%
1,900,000
+400,000
+27% +$1.44M
VALE icon
64
CALL
Vale
VALE
$62.3B
$6.12M 0.09%
+500,000
New +$5.31M
ALDR
65
DELISTED
Alder Biopharmaceuticals
ALDR
$5.72M 0.09%
500,000
– –
AGIO icon
66
CALL
Agios Pharmaceuticals
AGIO
$2.08B
$5.72M 0.09%
+100,000
New +$6.29M
MDCO
67
DELISTED
Medicines Co
MDCO
$5.47M 0.08%
200,000
-100,000
-33% -$3.08M
SYBX
68
DELISTED
Synlogic
SYBX
$5.33M 0.08%
+36,667
New +$6.97M
IMUX icon
69
Immunic
IMUX
$178M
$5.21M 0.08%
2,188
– –
PBYI icon
70
Puma Biotechnology
PBYI
$398M
$4.94M 0.07%
+50,000
New +$5.6M
NTLA icon
71
Intellia Therapeutics
NTLA
$1.51B
$4.8M 0.07%
250,000
+75,000
+43% +$1.73M
FCX icon
72
CALL
Freeport-McMoran
FCX
$86.2B
$4.74M 0.07%
+250,000
New +$3.77M
ADAP
73
DELISTED
Adaptimmune Therapeutics
ADAP
$4.68M 0.07%
700,000
+200,000
+40% +$1.54M
LRMR icon
74
Larimar Therapeutics
LRMR
$377M
$4.62M 0.07%
83,333
– –
JUNO
75
DELISTED
Juno Therapeutics, Inc.
JUNO
$4.57M 0.07%
100,000
-50,000
-33% -$2.49M
1 2
3
4 5

Similar funds

BCM
Bronte Capital Management Bondi Junction, Australia $1.01B AUM 47.99% 1-Year Est. Return
GA
GRS Advisors Chicago, Illinois $1.01B AUM 13.12% 1-Year Est. Return
EPAM
Euro Pacific Asset Management Dorado, Puerto Rico $1.01B AUM 79.26% 1-Year Est. Return
WA
Wealth Alliance Mellville, New York $1.01B AUM 19.71% 1-Year Est. Return
CT
Coastline Trust Providence, Rhode Island $1.01B AUM 22.57% 1-Year Est. Return
AH
Allen Holding New York $1.01B AUM 27.61% 1-Year Est. Return
PIM
Provident Investment Management Novi, Michigan $1.01B AUM 9.4% 1-Year Est. Return
MAM
Melqart Asset Management London, United Kingdom $1.01B AUM 84.85% 1-Year Est. Return

Artal Group's Q4 2017 Portfolio in Review

As of Q4 2017, Artal Group held 140 positions worth $6.63B, up 14% from $5.81B the previous quarter. Its ten largest holdings account for 83% of the portfolio.

Artal Group deployed $471M of net new capital in Q4 2017, opening 29 new positions and adding to 38 existing holdings. Its largest new stake was Denali Therapeutics: 500,000 shares worth $7.82M.

By sector, the portfolio is most concentrated in Consumer Staples at 43% of assets, up from 43% a quarter earlier, followed by Consumer Discretionary and Healthcare.

On the sell side, the largest reduction was Nektar Therapeutics, an estimated $33.5M trimmed.

  • Artal Group's largest Q4 2017 buy was Denali Therapeutics: 500,000 shares worth $7.82M.
  • Artal Group added most to Alnylam Pharmaceuticals in Q4 2017, an estimated $25.1M increase.
  • Artal Group's biggest Q4 2017 reduction was Nektar Therapeutics, cutting an estimated $33.5M.
  • Artal Group fully exited BioMarin Pharmaceuticals in Q4 2017, selling an estimated $17.4M.
  • Artal Group's ten largest holdings make up 83% of its $6.63B portfolio in Q4 2017.
  • Artal Group opened 29 new positions and closed 21 in Q4 2017.
  • Artal Group's portfolio value rose 14% quarter-over-quarter to $6.63B.

Based on Artal Group's 13F filing for Q4 2017, filed 9 Feb 2018.